128 related articles for article (PubMed ID: 37592047)
1. An analysis of the resource use and costs of febrile neutropenia events in pediatric cancer patients in Australia.
Vargas C; Haeusler GM; Slavin MA; Babl FE; Mechinaud F; Phillips R; Thursky K; Lourenco RA;
Pediatr Blood Cancer; 2023 Nov; 70(11):e30633. PubMed ID: 37592047
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of home-based care of febrile neutropenia in children with cancer.
Tew M; De Abreu Lourenco R; Gordon JR; Thursky KA; Slavin MA; Babl FA; Orme L; Bryant PA; Teh BW; Dalziel K; Haeusler GM
Pediatr Blood Cancer; 2022 Jul; 69(7):e29469. PubMed ID: 34854550
[TBL] [Abstract][Full Text] [Related]
3. Costs associated with febrile neutropenia in the US.
Michels SL; Barron RL; Reynolds MW; Smoyer Tomic K; Yu J; Lyman GH
Pharmacoeconomics; 2012 Sep; 30(9):809-23. PubMed ID: 22804805
[TBL] [Abstract][Full Text] [Related]
4. National cost savings from an ambulatory program for low-risk febrile neutropenia patients in Australia.
Tew M; Forster D; Teh BW; Dalziel K
Aust Health Rev; 2019 Oct; 43(5):549-555. PubMed ID: 31526466
[TBL] [Abstract][Full Text] [Related]
5. Febrile neutropenia-related care and associated costs in elderly patients with breast cancer, lung cancer, or non-Hodgkin lymphoma.
Li S; Liu J; Bowers C; Garawin TAFS; Kim C; Bensink ME; Chandler DB
Support Care Cancer; 2020 Jan; 28(1):113-122. PubMed ID: 30993450
[TBL] [Abstract][Full Text] [Related]
6. Neutropenia-related costs in patients treated with first-line chemotherapy for advanced non-small cell lung cancer.
Stokes ME; Muehlenbein CE; Marciniak MD; Faries DE; Motabar S; Gillespie TW; Lipscomb J; Knopf KB; Buesching DP
J Manag Care Pharm; 2009 Oct; 15(8):669-82. PubMed ID: 19803556
[TBL] [Abstract][Full Text] [Related]
7. Effect of outpatient treatment of febrile neutropenia on the risk threshold for the use of CSF in patients with cancer treated with chemotherapy.
Cosler LE; Sivasubramaniam V; Agboola O; Crawford J; Dale D; Lyman GH
Value Health; 2005; 8(1):47-52. PubMed ID: 15841893
[TBL] [Abstract][Full Text] [Related]
8. Clinical Outcomes of Treatment with Filgrastim Versus a Filgrastim Biosimilar and Febrile Neutropenia-Associated Costs Among Patients with Nonmyeloid Cancer Undergoing Chemotherapy.
Schwartzberg LS; Lal LS; Balu S; Campbell K; Brekke L; DeLeon A; Elliott C; Korrer S
J Manag Care Spec Pharm; 2018 Oct; 24(10):976-984. PubMed ID: 29687743
[TBL] [Abstract][Full Text] [Related]
9. Costs associated with febrile neutropenia in solid tumor and lymphoma patients - an observational study in Singapore.
Wang XJ; Wong M; Hsu LY; Chan A
BMC Health Serv Res; 2014 Sep; 14():434. PubMed ID: 25252614
[TBL] [Abstract][Full Text] [Related]
10. Outpatient treatment for people with cancer who develop a low-risk febrile neutropaenic event.
Rivas-Ruiz R; Villasis-Keever M; Miranda-Novales G; Castelán-Martínez OD; Rivas-Contreras S
Cochrane Database Syst Rev; 2019 Mar; 3(3):CD009031. PubMed ID: 30887505
[TBL] [Abstract][Full Text] [Related]
11. The cost of the inpatient management of febrile neutropenia in cancer patients--a micro-costing study in the Irish healthcare setting.
O'Brien C; Fogarty E; Walsh C; Dempsey O; Barry M; Kennedy MJ; McCullagh L
Eur J Cancer Care (Engl); 2015; 24(1):125-32. PubMed ID: 24472035
[TBL] [Abstract][Full Text] [Related]
12. [Modalities of management of cancer patients with febrile neutropenia in the oncology emergency unit of Gustave-Roussy and their related costs].
Borget I; Antoun S; Chachaty E; Gachot B; Alibay A; Di Palma M; Merad M
Bull Cancer; 2014 Oct; 101(10):925-31. PubMed ID: 25373692
[TBL] [Abstract][Full Text] [Related]
13. Aminoglycoside use in paediatric febrile neutropenia - Outcomes from a nationwide prospective cohort study.
McMullan BJ; Haeusler GM; Hall L; Cooley L; Stewardson AJ; Blyth CC; Jones CA; Konecny P; Babl FE; Mechinaud F; Thursky K;
PLoS One; 2020; 15(9):e0238787. PubMed ID: 32936822
[TBL] [Abstract][Full Text] [Related]
14. Potential reduction of hospital stay length with outpatient management of low-risk febrile neutropenia in a regional cancer center.
Nguyen M; Jacobson T; Torres J; Wann A
Cancer Rep (Hoboken); 2021 Jun; 4(3):e1345. PubMed ID: 33635593
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy-Induced Neutropenia and Febrile Neutropenia in the US: A Beast of Burden That Needs to Be Tamed?
Boccia R; Glaspy J; Crawford J; Aapro M
Oncologist; 2022 Aug; 27(8):625-636. PubMed ID: 35552754
[TBL] [Abstract][Full Text] [Related]
16. Patient out-of-pocket and payer costs for pegfilgrastim originator vs biosimilars as primary prophylaxis of febrile neutropenia in the first cycle among a commercially insured population.
Wang CY; Park H; Heldermon CD; Vouri SM; Brown JD
J Manag Care Spec Pharm; 2022 Jul; 28(7):795-802. PubMed ID: 35737859
[No Abstract] [Full Text] [Related]
17. A retrospective study of the clinical and economic burden during hospitalizations among cancer patients with febrile neutropenia.
Dulisse B; Li X; Gayle JA; Barron RL; Ernst FR; Rothman KJ; Legg JC; Kaye JA
J Med Econ; 2013; 16(6):720-35. PubMed ID: 23452298
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of step-down to oral outpatient treatment versus inpatient antimicrobial treatment in pediatric cancer patients with febrile neutropenia: A noninferiority multicenter randomized clinical trial.
Avilés-Robles MJ; Reyes-López A; Otero-Mendoza FJ; Valencia-Garin AU; Peñaloza-González JG; Rosales-Uribe RE; Muñoz-Hernández O; Garduño-Espinosa J; Juárez-Villegas L; Zapata-Tarrés M
Pediatr Blood Cancer; 2020 Jun; 67(6):e28251. PubMed ID: 32196898
[TBL] [Abstract][Full Text] [Related]
19. Predicting Infectious ComplicatioNs in Children with Cancer: an external validation study.
Haeusler GM; Thursky KA; Mechinaud F; Babl FE; De Abreu Lourenco R; Slavin MA; Phillips R
Br J Cancer; 2017 Jul; 117(2):171-178. PubMed ID: 28609435
[TBL] [Abstract][Full Text] [Related]
20. Outpatient versus inpatient IV antibiotic management for pediatric oncology patients with low risk febrile neutropenia: a randomised trial.
Orme LM; Babl FE; Barnes C; Barnett P; Donath S; Ashley DM
Pediatr Blood Cancer; 2014 Aug; 61(8):1427-33. PubMed ID: 24604835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
